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Introduction
  Increased portal pressure is related to multiple complications 
in liver cirrhosis, and the renin–angiotensin–aldosterone sys-
tem plays important roles in portal hypertension.[1] Fimasartan 
is a nonpeptide angiotensin II receptor blocker with a selective 
type 1 receptor blocking effect.[2] It is rapidly absorbed after 
oral administration with a peak plasma concentration at 0.5–3.0 
h,[3] and its exposure is dose proportional with a terminal 
elimination half-life ranging from 5 to 16 h in healthy subjects.
[3] The absolute bioavailability of orally administered fimasar-
tan in healthy subjects is 18.6%,[4] and its protein binding is 
about 96%.[5] Most of the circulating fimasartan in plasma is in 
the parent form, although fimasartan is catabolized by multiple 
cytochrome P450s (CYP), mainly CYP3A4, UDP-glucuronos-
yltransferases, and other enzymes.[6] The urinary excretion of 
unchanged fimasartan is <3% over the first 24 h after adminis-
tration, and it is mostly excreted into the bile as either parent or 
in a glucuronide conjugated form.[7]
  We have reported the pharmacokinetics (PK) and safety of 
fimasartan in patients with hepatic impairment compared with 
healthy subjects.[8] After a single oral administration of fima-
sartan, subjects with mild hepatic impairment appeared to show 
exposure similar to that of healthy individuals, whereas subjects 
with moderate hepatic impairment exhibited approximately 6.6-
fold and 5.2-fold increase in the peak concentration (Cmax) and 
area under the time–concentration curve (AUC) of fimasartan, 
respectively.[8] Based on the results of this study, the Ministry 
of Food and Drug Safety in Korea approved the label of fima-
sartan stating that it should not be administered to subjects with 
moderate-to-severe hepatic impairment. However, the change 
in blood pressure showed a pattern similar to those of healthy 
Fimasartan is a nonpeptide angiotensin II receptor blocker. In a previous study that compared the 
pharmacokinetics (PK) of fimasartan between patients with hepatic impairment (cirrhosis) and 
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blood pressure (BP) was not clinically significant in those with moderate hepatic impairment. The 
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and to evaluate the effect of hepatic function on BP reduction by fimasartan using previously pub-
lished data. A 2-compartment linear model with mixed zero-order absorption followed by first-
order absorption with a lag time adequately described fimasartan PK, and the effect of fimasartan 
on BP changes was well explained by the inhibitory sigmoid function in the turnover PK-PD model 
overlaid with a model of circadian rhythm (NONMEM version 7.2). According to our PD model, 
the lower BP responses in hepatic impairment were the result of the increased fimasartan EC50 in 
patients, rather than from a saturation of effect. This is congruent with the reported pathophysi-
ological change of increased plasma ACE and renin activity in hepatic cirrhosis.
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individuals despite the Cmax and AUC of fimasartan being high-
er in subjects with moderate hepatic impairment. Results of this 
study imply that fimasartan might not cause serious BP reduc-
tion despite the higher exposure in those with moderate hepatic 
impairment. Thus, we aimed to clarify the long-term influence 
of increased fimasartan exposure on the BP of patients quanti-
tatively by developing a population PK-pharmacodynamic (PD) 
model using previously published data.[8]
Methods
  The PK and PD (blood pressure) data of fimasartan reported 
previously[8] was used to develop PK and PK-PD models. The 
design of the clinical trial is summarized as following.
  An open-label, single-dose, parallel study was conducted using 
a total of 18 subjects in three groups (mild hepatic impairment, 
moderate hepatic impairment, and healthy group). Six subjects 
were each assigned to the mild and moderate hepatic impair-
ment group depending on their Child–Pugh score: 5–6 for mild 
and 7–9 for moderate hepatic impairment. Six healthy individu-
als participated after completion of hepatic impairment group 
schedule. After a single administration of fimasartan (120 mg 
orally), serial blood samples for PK were collected in heparin-
ized tubes before dosing, and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 
16, 24, 32, and 48 h after dosing. SBP and DBP were measured 
before dosing, and 1, 2, 3, 4, 8, 12, 24, 32, and 48 h after dosing. 
All subjects had rested in a sitting position for at least 5 min be-
fore BP was measured.
Model development
  NONMEM version 7.2 (Icon Development Solutions, Ellicott 
City, MD, USA) was used to conduct population PK-PD model-
ing based on the first-order conditional estimation with interac-
tion method (FOCE-INTER). The population PK–PD model 
was developed sequentially. Population PK model was initially 
developed, and then the population PD model was developed 
using a dataset added to the individual PK parameters estimated 
from the final PK model.
Population PK model
  Drug elimination was assumed to follow the first-order kinet-
ics. Based on the first-order kinetics, one- or two-compartment 
distribution models were assessed. First-order, zero-order, 
mixed first-order and zero-order, transit compartment, and en-
terohepatic recycling models were explored to identify the best 
one to describe the absorption of fimasartan. Each parameter 
was assumed to be log–normally distributed and described as: 
Pij = θj exp(ηij) where Pij is the j-th parameter for the i-th indi-
vidual, θj is typical value for the j-th population parameter, and 
ηij is a random variable following a Gaussian distribution with 
a mean of 0 and variance of ω2. An additive, proportional, and 
combined residual error model were tested. The appropriate-
ness of the model was comprehensively evaluated by consider-
ing: likelihood-ratio tests, physiological plausibility, goodness-
of-fit diagnostics, and measures of model stability and adequacy 
including condition number, successful convergence, significant 
digits, and matrix singularity. Likelihood-ratio test results were 
considered statistically significant if decreases in the objective 
function value (OFV) of nested models were more than 3.84 
(P < 0.05, one degree of freedom) and 5.99 units (P < 0.05, two 
degrees of freedom).
  After the base structural model was built, covariates were ex-
plored to develop the model with the best overall performance 
using a stepwise forward selection and backward elimination 
process. Covariates included age, body weight, albumin, total 
bilirubin, aspartate transaminase (AST), alanine transaminase 
(ALT), γ-glutamyl transpeptidase, creatinine, and prothrombin 
time (INR units). All of these covariates were continuous and 
were centered on their median values. The covariate was con-
sidered significantly associated with the PK parameter if both of 
the OFV decrease and physiological plausibility were satisfied. 
With those significant covariates, the forward selection and 
backward elimination process was used.
Population PD model
  The circadian rhythm of BP over 24 h was incorporated into 
the baseline PD model using a method reported previously.[9]
where Bsl(t) represents the baseline BP as a function of clock 
time (t), MESOR is the rhythm-adjusted 24 h mean BP, Ampi 
is the i-th amplitude parameter of the cosine function, and ACi 
is the i-th phase shift parameter of the cosine function. In this 
step, Ampi and ACi were fixed to the estimates in the report,[9] 
and MESOR in each  subject was calculated using the measured 
Bsl(0) (the baseline BP at time 0) of each  subject and the fixed 
Ampi and ACi on the right-hand side of the equation above.
  Fimasartan is an antihypertensive drug, and the effect of the 
drug was applied in the model as an inhibitory function. In-
terindividual variability of PD parameters were assumed to 
follow a log–normal distribution with a mean 0 and variance ω, 
and the residual error was described by an additive model. The 
turnover, effect compartment, and transduction models were 
compared. Because the turnover model best described the time 
delay between plasma concentration and BP responses, BP of 
subjects was described by an equilibrium between endogenous 
tendencies (stimuli) to elevate and to lower BP.
  Rate of BP change = kin∙E(C) – Kout∙A(4),
where Kin is the zero-order constant for BP increase and E(C) 
is the drug effect, Kout is the first-order rate constant for BP de-
crease, and A(4) is the amount in the compartment represent-
ing BP.
  Fimasartan was assumed to exert its effect by inhibiting the 
stimuli to elevate BP. The drug effect, E(C), was considered as 
an inhibitory sigmoid function:
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where Emax is the maximum effect (0≤Emax≤1), and EC50 is the 
plasma concentration required for 50% maximal inhibition. 
The influences of disease severity on Emax or EC50 were screened 
by comparing the OFVs after incorporating three combinations 
of subject groups: healthy, mild, moderate; healthy, (mild and 
moderate); (healthy and mild), moderate.
Model evaluation and simulation
  Using the final PK and PD models, 1,000 
bootstrap-resampled datasets were estimated 
to calculate the mean and 95% CIs for popula-
tion PK and PD parameters. A visual predic-
tive check (VPC) using 1,000 simulated datas-
ets was conducted in each PK and PD model. 
The 90% prediction intervals of simulated data 
were overlaid with the observed data.
Results
Study subject subjects
  A total of 18 subject subjects (six each in 
healthy, mild hepatic impairment, and moder-
ate hepatic impairment groups) completed 
the trial. There were 288 observation points 
for plasma fimasartan concentration and 180 
collected datum points for BP. There were no 
statistical differences in age, body weight, or 
height between the groups (P>0.05, Table 1). Subjects in the 
group with moderate hepatic impairment showed significantly 
higher bilirubin and lower albumin than in other groups, and a 
prolonged prothrombin time (P<0.05, Table 1).
Population pharmacokinetic analysis
  The plasma concentration of fimasartan was best described by 
a 2-compartment, first-order elimination model with a propor-
tional residual error. Because multiple plasma concentration 
Table 1. Demographic characteristics at baseline
Data are given mean ± SD (min–max). Abbreviation: Mild, mild hepatic impairment; Moderate, moderate hepatic impairment; NA, not applicable. 
aP-values for differences between the healthy, mild hepatic impairment, and moderate hepatic impairment groups were calculated using a Kruskal–
Wallis test. Multiple comparisons by Tukey’s test were also conducted for variables, which were identified as significant by the Kruskal–Wallis test. 
b, c, d, e, f, gP < 0.05 by multiple comparison analysis.
Healthy (n = 6) Mild (n = 6) Moderate (n = 6) aP
Age (years)
48.8 ± 3.8
(45–56)
43.2 ± 10.5
(26–56)
48.2 ± 7.2
(39–56)
0.502
Height (cm)
172.0 ± 5.6
(165–180)
172.0 ± 7.2
(163–180)
169.2 ± 3.7
(164–175)
0.243
Body weight (kg)
71.8 ± 4.2
(67.0–77.0)
70.3 ± 7.4
(65.0–85.0)
65.6 ± 8.3
(57.0–79.0)
0.611
Bilirubin (mg/dL)
0.9 ± 0.4b,c
(0.5–1.6)
1.2 ± 0.4b
(0.5–1.7)
2.5 ± 1.8c
(1.0–6.0)
0.012
Albumin (g/dL)
4.5 ± 0.2d
(4.3–4.7)
4.6 ± 0.5e
(4.0–5.1)
3.1 ± 0.5d,e
(2.3–3.6)
0.003
Prothrombin time (INR)
0.95 ± 0.03f,g
(0.92–1.00)
1.04 ± 0.15f
(0.87–1.26)
1.25 ± 0.23g
(0.99–1.65)
0.010
Child–Pugh score (range) NA 5–6 7–9 NA
Figure 1. The structure of the pharmacokinetic and pharmacodynamics models for fima-
sartan. Notes: (1) 0 < time < D2, zero-order input; (2) first-order input after ALAG, Abbre-
viations: Ka, rate of constant for first-order absorption; Q/F, intercompartmental clearance; 
CL/F, clearance; kin, input rate for production of response; kout, first-order rate constant for 
loss of response; BP, blood pressure; D2, duration of absorption for the zero-order ab-
sorption process; ALAG, lag time before first-order absorption.
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peaks were shown after a single oral administration of fimasar-
tan, some absorption models were explored. Among them, the 
mixed zero-order absorption followed by first-order absorption 
with a lag time best described the absorption of fimasartan. The 
overall structure of PK and PD is presented in Figure 1.
  The mean Cmax of the group with moderate hepatic impair-
ment was 6.6 times that of the group of healthy individuals, 
unlike the group with mild hepatic impairment.[8] To describe 
this difference of absorption characteristics according to hepatic 
dysfunction, we introduced another fixed effect term IL (incre-
Table 2. Final estimates of population pharmacokinetic parameters
Notes: a95% CI was estimated by applying the final population pharmacokinetic model to 1,000 resampled datasets. Abbreviation: %RSE, relative 
standard error; CI, confidence interval; CV, coefficient of variation; BSV, between-subject variability; NA, not applicable.
Parameter Description (unit) Estimate %RSE Bootstrap median(95% CI)a
Structural model
CL Clearance (L/h) 27.0 13.3 27.1
(21.8–38.7)
V2
Volume of central compartment (L)
48.7 20.4 46.8
(28.2–96.0)
V3
Volume of peripheral compartment (L)
46.5 11.1 47.4
(30.5–68.7)
Ka Absorption rate constant (h–1) 0.319 16.3 0.320
(0.220–0.518)
Q
Intercompartmental clearance (L/h)
3.40 12.4 3.62
(2.28–6.33)
D2
Virtual duration of dosing for zero order absorption (h)
0.583 9.8 0.598
(0.500–0.742)
LAG
Lag time for first-order absorption (h)
2.0 0.1 2.0
(1.4–2.5)
F = 0.18 + IL
IL1 Increased bioavailability compared with healthy  subject in mild 
hepatic impairment group
0.0873 142.1 0.084 
(0.001–0.668)
IL2 Increased bioavailability compared with healthy  subject in mod-
erate hepatic impairment group
0.896 19.7 0.895 
(0.607–1.481)
F2 = α*F
α Proportionality constant for fraction of zero-order absorption 
process (F2)
0.642 7.4 0.633 
(0.455–0.799)
Interindividual variability (ω, CV%)
ωCL/F BSV on CL/F 39.9 15.8 35.8 
(12.2–67.2)
ωV2/F BSV on V2/F 121.4 41.3 89.9 
(16.1–166.8)
ωKa BSV on Ka 63.5 18.0 49.3 
(5.0–74.6)
ωa BSV on α 69.5 43.8 61.5 
(6.0–152.0)
Residual error
σadd Additive error 0.0001 
fix
NA NA
σprop Proportional error 0.354 8.8 0.350 
(0.122–0.672)
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ment by liver disease: IL1 for mild, and IL2 for moderate liver 
disease) into the structural PK model. Based on a previous re-
port,[4] the absolute bioavailability (F) of fimasartan in healthy 
subjects was fixed to 0.18 in our PK model. Thus, 
F was estimated as 0.18 (fixed for healthy subjects), 
0.18 + IL1 for mild and 0.18 + IL2 for moderate 
liver disease. F was also assumed to be the sum of 
F1 and F2 (F = F1 + F2), the fractions absorbed 
by first-order and zero-order inputs, respectively. 
For simplicity, the relationship was rewritten to F 
= F1 + F2 = (1 – α) F + αF, and we estimated α as a 
coefficient between 0 and 1. The final population 
PK parameter estimates are summarized in Table 2. 
Basic goodness-of-fit plots for the final PK model 
are shown in Figure 2.
Population pharmacodynamic analysis
  The parameter estimates for the BP circadian 
rhythm were presented in Table 3. In our final model, the BP 
was the sum of circadian changes and drug effects:
  BP(t) = Bsl(t) + A(4)(t) – MESOR
Table 3. Parameter estimates derived from the change in the blood pressure of 
healthy volunteers from baseline
Abbreviation: BP, blood pressure.
Parameter Systolic BP Diastolic BP
Rhythm adjusted 24 h mean BP (mmHg) 116 65.3
Amplitude, first cosine term (%) –10.2 –13.8
Amplitude, second cosine term (%) 4.47 6.39
Phase shift, first cosine term (h) –3.44 –3.56
Phase shift, second cosine term (h) 2.42 2.28
Residual error (additive) 0.103 0.060
A B
C
Figure 2. Goodness-of-fit plots for the final population pharmacokinetic and pharmacodynamic models of fimasartan. Notes: (A) Plasma concen-
tration of fimasartan; (B) systolic blood pressure; (C) diastolic blood pressure. Black line indicates identity, and gray line indicates locally-weighted 
regression smooth line. Abbreviation: IWRES, individual weighted residuals.
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where BP(t) is the change of BP over time (t), and A(4)(t) is also 
a function of time. The final parameters of population PD are 
summarized in Table 4, and basic goodness-of-fit plots of the fi-
nal PD models (SBP and DBP) are shown in Figure 2. The EC50 
was found to be increased in subjects with hepatic impairment 
compared with that in healthy subjects (Table 4).
Model evaluation and simulation
  The median estimates of PK and PD parameters obtained 
from bootstrapping were nearly identical to the final parameter 
estimates (Table 2 and 4). VPC plots of PK and PD model are 
presented in Figures 3 and 4, respectively. Most of the observed 
concentrations or BP data (SBP and DBP) were within the 90% 
prediction intervals in VPC for PK and PD.
Discussion
  Even though the exposure to fimasartan in subjects with 
moderate hepatic impairment was about 5–6 fold higher than 
in healthy subjects after oral administration in the previous 
study,[8] BP did not decrease as much as plasma concentra-
tion change. Thus, we developed a population PK-PD model of 
fimasartan to evaluate the effect of hepatic function on the BP 
reduction, and predicted the BP change after 30-day oral ad-
ministration of fimasartan 120 mg once daily.
Table 4. Final estimates of population pharmacodynamic parameters
Notes: a95% CI was estimated by applying the final population pharmacodynamic model to 1,000 resampled datasets. bKout = Kin/Base. Abbrevia-
tion: %RSE, relative standard error; CI, confidence interval; CV, coefficient of variation; BSV, between-subject variability; NA, not applicable.
Parameter Description (unit) Estimate RSE Bootstrap median (95% CI)a
Systolic blood pressure
Structural model
Kin Input rate for production of response (mmHg/h) 90.3 17.7 89.2 (63.7–121.1)
Emax Maximum effect (%) 21.3 5.8 21.6 (19.3–24.2)
Base Predose blood pressure (mmHg) 131.0 2.0 131.0 (126.0–137.0)
EC50 Drug concentration that produces 50% of maximal effect
EC50,H EC50 in healthy subject group (ng/mL) 2.28 20.7 2.36 (1.50–3.93)
EC50, A+B EC50 in mild and moderate hepatic impairment groups (ng/mL) 9.19 53.8 9.74 (3.55–30.61)
  Kout
b First-order rate constant for loss of response (h–1) 0.69 NA NA
Interindividual variability (ω, CV%)
ωBase BSV on Base (%) 5.3 36.3 5.1 (3.2–7.3)
Residual error
σprop Proportional error 0.063 6.2 0.061 (0.054–0.069)
Diastolic blood pressure
Structural model
 Kin Input rate for production of response (mmHg/h) 33.1 19.7 33.6 (23.7–56.2)
 Emax Maximum effect (%) 33.8 8.7 33.9 (28.7–40.7)
 Base Predose blood pressure (mmHg) 82.3 3.3 82.5 (77.1–88.1)
 EC50 Drug concentration that produces 50% of maximal effect  
EC50,H+A EC50 in healthy subject and mild hepatic impairment groups (ng/mL) 4.82 40.5 4.64 (1.81–12.51)
EC50, B EC50 in moderate hepatic impairment group (ng/mL) 47.3 51.8 42.1 (10.8–140.1)
Kout
b First-order rate constant for loss of response (h–1) 0.40 NA NA
Interindividual variability (CV%)
ωBase BSV on Base (%) 1.25 35.6 10.8 (6.6–14.5)
ωEC50 BSV on EC50 (%) 56.8 55.3 62.8 (0.8–106.8)
Residual error
σadd Additive error (mmHg) 6.27 6.8 6.2 (5.4–7.0)
σprop Proportional error 0.0001 fix NA NA
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  In this study, fimasartan plasma concentration–time profiles 
have shown a pattern of rapid initial rise, second peak, and bi-
exponential decline after oral administration. In addition, the 
initial increase to Cmax was the most distinct in those subjects 
with moderate hepatic impairment, whereas the elimination 
rate constants were similar between the study groups. Fimasar-
tan is eliminated mostly to feces via biliary excretion by organic 
anion-transporting polypeptides, it is also metabolized primar-
ily by CYP3A4.[4,5,10] Only two subjects in the group with 
mild hepatic impairment were diagnosed with liver cirrhosis, by 
contrast, all of the subjects in the group with moderate hepatic 
impairment group were patients with chronic liver cirrhosis. 
Therefore, this discrepancy in absorption profiles according to 
study group could be the result of the cirrhotic disease in the 
patient subjects. The hepatic extraction ratio of fimasartan was 
assumed to be approximately 0.47,[4] and in cirrhotic  subjects 
with moderate hepatic dysfunction, liver disease could have af-
fected fimasartan absorption and elimination via a pathophysi-
ological change as follows: a reduction in the first-pass effect 
through extrahepatic or intrahepatic shunting of blood, hepa-
tocyte dysfunction, change in serum protein levels, and changes 
in bile flow.[11] To explain the differences in bioavailability ac-
cording to hepatic function, we applied the bioavailability rela-
tive to that of healthy subjects, IL, into the structural PK model. 
A
C
B
D
Figure 3. Visual predictive check plots for the final pharmacokinetic model. Notes: (A) Healthy subjects, (B) subjects with mild hepatic impairment, 
(C) subjects with moderate hepatic impairment, (D) total study population. Solid lines indicate median predicted concentration, and dotted dashed 
lines indicate 5th and 95th percentile predicted concentration.
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Based on a previous report,[4] we assumed that the bioavailabil-
ity in healthy individuals was fixed to 0.18, and bioavailability in 
patients was estimated relative to that in healthy subjects in each 
group with hepatic dysfunction.
  We compared a few absorption models to find the model 
which best describes the second peak phenomena. The second 
peaks were also observed after intravenous administration in 
other clinical trials, suggesting the presence of enterohepatic 
recirculation.[3,7,12] The empirical model of two-compartment 
distribution and mixed zero-order absorption followed by first-
order absorption with a lag time best described PK characteris-
tics of fimasartan in this study. This may have been the result of 
insufficient data to develop a physiological model incorporating 
the enterohepatic recirculation. The absorption model selected 
in this study has been used for other fimasartan modeling.[13]
  Age and body weight are correlated with the exposure or PK 
parameters of fimasartan.[13,14] We explored covariates after 
building the structural PK model; however, none of the covari-
ates was incorporated into the PK model. This may be the result 
of the strict inclusion and exclusion criteria in this study. There 
were no significant differences in age and body weight between 
the three groups (Table 1). A few laboratory variables such as 
total bilirubin, albumin, and PT were significantly different 
among study groups, but none of these was selected as a covari-
ate.
  BP fluctuates over 24 h following a circadian rhythm, and it is 
important to consider the circadian rhythm of BP to incorpo-
rate into the PD model with antihypertensive agents. Twenty-
four-hour ambulatory blood pressure measurements (ABPM) 
reveal a significant circadian variation in BP, and it is recom-
mended that the effect of drugs on BP response be evaluated.[15] 
Because our study did not assess 24-h ABPM, we applied the 
baseline circadian rhythm of BP reported in a previous study (of 
healthy Koreans) into our PD model.[9]
  There was a counterclockwise hysteresis between the mean 
plasma fimasartan concentration and BP, suggesting a lag in 
the time to the maximum effect (data not shown). Fimasartan 
is an angiotensin receptor blocker, and the effect is exerted by 
inhibiting the renin–angiotensin–aldosterone system. Based on 
the pharmacological mechanism of fimasartan, a transit model 
would be more mechanistic than others. However, a turnover 
model was the best to explain our data as it was in a previous 
study of healthy Korean subjects.[9] The sparseness of BP data 
may be the reason why the PK and PD data do not support the 
transit model.
  Using the final PK-PD model, simulations were performed 
to investigate the effect on BP according to the severity of he-
patic dysfunction. The plasma concentrations of fimasartan 
have fallen below the EC50 12 h after administration in hepatic 
impairment patients whose EC50 values were higher than those 
in healthy subjects (Table 4). The discrepancy in effect by he-
patic disease severity was similar to those found in a study of 
the angiotensin-converting enzyme (ACE) inhibitor, cilazapril.
[16] Cilazapril concentrations were higher in subjects with he-
patic impairment, but the BP responses were similar to those 
of healthy individuals. Patients with cirrhosis had significantly 
higher predrug plasma ACE and renin activity than that in 
healthy controls.[16] There are a few reports regarding the high-
er activity of ACE and renin in patients with cirrhosis,[1,17] 
and all of our  subjects with moderate hepatic dysfunction were 
diagnosed as having liver cirrhosis. Therefore, we speculate that 
augmented BP lowering effects are not likely to occur in patients 
A B
Figure 4. Visual predictive check plots for the final pharmacodynamic model. Notes: (A) SBP: Predicted median and 90% confidence interval for 
each group. (B) DBP: Predicted median and 90% confidence interval for each group. Abbreviations: A, group with mild hepatic impairment; B, group 
with moderate hepatic impairment; H, group of healthy  subjects; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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with liver cirrhosis following 120 mg of fimasartan despite their 
higher exposure to the drug.
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